Details of Disease

General Information of Disease (ID: DIS4UWVC)

• Disease Name: Coronary artery disease
• Disease Class: BA80: Coronary atherosclerosis
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DIS4UWVC: Coronary artery disease
• ICD Code:
  ICD-11: ICD-11: BA80
  ICD-10: ICD-10: I25.1, I25.4
  ICD-9: ICD-9: 414
  Expand ICD-11: 'BA8Z
  Expand ICD-10: 'I25.1; 'I25.4
  Expand ICD-9: 414
• Disease Identifiers:
  MONDO ID: MONDO_0044875
  MESH ID: D017566
  UMLS CUI: C0206064
  MedGen ID: 104771
  SNOMED CT ID: 233845001

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 7 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ammonia	DMOEVK6	Approved	Small molecular drug	[1]
Arbutamine	DMCY8AF	Approved	Small molecular drug	[2]
Biolimus a9	DM9X4TT	Approved	Small molecular drug	[3]
Iodine-123-iodophenylpentadecanoic acid	DM2QN6U	Approved	NA	[4]
Probucol	DMVZQ2M	Approved	Small molecular drug	[5]
Rubidium chloride Rb82	DM1ZS8J	Approved	NA	[4]
Trapidil	DMY67U8	Phase 4	Small molecular drug	[6]

This Disease is Treated as An Indication in 27 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Apadenoson	DMD8QTC	Phase 3	Small molecular drug	[7]
DMP-444	DMO7BQS	Phase 3	NA	[8]
Ridaforolimus eluting coronary stent	DM4Z6UO	Phase 3	NA	[3]
ZK-205367	DMUS0V1	Phase 2/3	NA	[9]
VX-702	DMKJDR6	Phase 2a	Small molecular drug	[10]
ACCLAIM	DM0FGDO	Phase 2	Small molecular drug	[11]
AVI-5126	DMUOYQR	Phase 2	Antisense drug	[12]
AZD5718	DM9GWZH	Phase 2	NA	[3]
CardioPET	DMSQ4Z7	Phase 2	NA	[13]
CVBT-141H	DMYPXQ2	Phase 2	NA	[14]
Gadocoletic acid	DMSZCNP	Phase 2	Small molecular drug	[15]
IMB-101	DMLY1NQ	Phase 2	NA	[16]
ISIS-APO(a)	DMQ3C05	Phase 2	Antisense drug	[17]
ISIS-CRPRx	DML84CN	Phase 2	NA	[18]
MEDI5884	DMW7Y28	Phase 2	NA	[3]
MEDI6012	DMU4CS8	Phase 2	NA	[3]
REG-101	DMG9375	Phase 2	NA	[19]
Resten-MP	DMD7E29	Phase 2	NA	[20]
Resten-NG	DMM4EJI	Phase 2	Antisense drug	[21]
SUN N4057	DMO9LBE	Phase 2	Small molecular drug	[22]
LT-1951	DM5N04G	Phase 1/2	NA	[23]
BFPET	DMBDVPR	Phase 1	NA	[24]
Coronary artery disease gene therapy	DMBH694	Phase 1	NA	[25]
ISIS-APOARx	DMX5T1L	Phase 1	NA	[26]
Myolimus	DMDZ7S0	Phase 1	NA	[27]
ZK-200775	DM2LHPU	Phase 1	Small molecular drug	[28]
COMBO Stent	DMADR32	Clinical trial	NA	[3]

This Disease is Treated as An Indication in 7 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
FENDILINE	DMH6NG5	Withdrawn from market	Small molecular drug	[29]
EF-12	DMKI0CO	Discontinued in Phase 3	NA	[30]
RB-006	DMAINU1	Discontinued in Phase 3	NA	[31]
Cromafiban	DMZLIUQ	Discontinued in Phase 2	NA	[32]
CAB-2	DMQ4HUA	Discontinued in Phase 1	NA	[33]
CT-3501	DMQV01X	Terminated	NA	[35]
SDZ-87-469	DMBY6CQ	Terminated	Small molecular drug	[36]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BMS-PCSK9	DMRCMEK	Preclinical	Antisense drug	[34]

This Disease is Treated as An Indication in 3 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
1D05	DMGSQTK	Investigative	Antibody	[37]
CVT-012000	DMXML6G	Investigative	NA	[38]
VasoPET	DMG7AW0	Investigative	NA	[38]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
• [2] Drug information of Arbutamine, 2008. eduDrugs.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7277).
• [6] ClinicalTrials.gov (NCT00914420) Optical Coherence Tomography (OCT) Evaluation of Re-endothelization: A Comparison of the Intrepide Stent Versus Taxus . U.S. National Institutes of Health.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290).
• [8] Evaluation of 99mTc-labeled cyclic RGD peptide with a PEG4 linker for thrombosis imaging: comparison with DMP444. Bioconjug Chem. 2011 Aug 17;22(8):1715-22.
• [9] Endothelial nitric oxide synthase gene therapy for erectile dysfunction. Curr Pharm Des. 2005;11(31):4059-67.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6059).
• [11] ClinicalTrials.gov (NCT01116427) A Cooperative Clinical Study of Abatacept in Multiple Sclerosis. U.S. National Institutes of Health.
• [12] ClinicalTrials.gov (NCT00451256) Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG). U.S. National Institutes of Health.
• [13] ClinicalTrials.gov (NCT01826773) CardioPET as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects. U.S. National Institutes of Health.
• [14] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020529)
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019307)
• [16] ClinicalTrials.gov (NCT04826172) A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease. U.S.National Institutes of Health.
• [17] ClinicalTrials.gov (NCT02160899) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Patients With High Lipoprotein(a). U.S. National Institutes of Health.
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024563)
• [19] Clinical pipeline report, company report or official report of Regio Biosciences
• [20] ClinicalTrials.gov (NCT00248066) Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries. U.S. National Institutes of Health.
• [21] Technology evaluation: AVI-4126, AVI BioPharma. Curr Opin Mol Ther. 2004 Oct;6(5):551-8.
• [22] ClinicalTrials.gov (NCT00272909) Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI). U.S. National Institutes of Health.
• [23] ClinicalTrials.gov (NCT00264706) PolyArginine Treated vEiN grafTs (PATENT). U.S. National Institutes of Health.
• [24] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027980)
• [25] Clinical pipeline report, company report or official report of BioCardia South.
• [26] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
• [27] ClinicalTrials.gov (NCT02086006) Elixir Medical Clinical Evaluation of the DESolve Myolimus Eluting Bioresorbable Coronary Stent System - DESolve I Trial. U.S. National Institutes of Health.
• [28] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7636).
• [29] Value of fendiline in the treatment of patients with stable angina pectoris. Pol Tyg Lek. 1987 Nov 16;42(46):1456-8.
• [30] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005941)
• [31] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019932)
• [32] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010404)
• [33] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010210)
• [34] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
• [35] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008030)
• [36] Chemotherapy of fungal diseases. 1990. Page(525-550).
• [37] A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res. 2011 Jan;52(1):78-86.
• [38] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.